Results: 4

1.
Figure 2

Figure 2. Study design.. From: Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco.

Participants were randomly assigned to one of four arms. Participants in the 2 immediate arms (TDF vs. placebo) initiated study drug at enrollment; those in the 2 delayed arms (TDF vs. placebo) initiated study drug at the 9 month visit. TDF, tenofovir disoproxil fumarate.

Albert Y. Liu, et al. PLoS One. 2011;6(8):e23688.
2.
Figure 4

Figure 4. Normal curves demonstrating percent changes in bone density at 24 months in the placebo vs. TDF groups, by anatomic site.. From: Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco.

Distribution curves of percent BMD change from baseline at last scan at the femoral neck (a), total hip (b), L2–L4 spine (c). BMD, bone mineral density;TDF, tenofovir disoproxil fumarate.

Albert Y. Liu, et al. PLoS One. 2011;6(8):e23688.
3.
Figure 3

Figure 3. Mean percent change in BMD from baseline at the total spine, total hip, and femoral neck.. From: Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco.

Trajectory of mean percent change in BMD at the femoral neck (a), total hip (b), and L2–L4 spine (c), by treatment arm. Solid lines represent the immediate arm, and dashed lines represent the delayed arm. Participants who discontinued study drug due to >5% BMD loss from baseline are included. BMD, bone mineral density.

Albert Y. Liu, et al. PLoS One. 2011;6(8):e23688.
4.
Figure 1

Figure 1. Study design and participant disposition.. From: Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco.

The baseline only cohort shown in red shading includes 26 men who had only 1 DEXA scan performed, either during screening or after enrollment. The longitudinal cohort shown in green shading includes 184 men who had a baseline and at least 1 additional scan during study follow-up. Of the 210 participants who had a baseline DEXA scan, 178 had this scan performed during screening, and 32 shortly after enrollment (prior to the protocol amendment moving DEXA scans to screening). †Delayed arm participants who enrolled prior to protocol amendment had baseline DEXA performed at 9 months prior to starting study drug. DEXA, dual energy X-ray absorptiometry; TDF, tenofovir disoproxil fumarate.

Albert Y. Liu, et al. PLoS One. 2011;6(8):e23688.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk